文献速递血液净化与透析

每周标准Kt/Vurea与居家及中心血液透析临床结局

Weekly Standard Kt/Vurea and Clinical Outcomes in Home and In-Center Hemodialysis.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-01-11

本研究纳入居家透析2373例和中心透析109273例患者,分析每周标准Kt/Vurea与血压、代谢控制及死亡等结局的关联。结果显示该指标与代谢控制无关;居家透析中与死亡、住院或转中心透析无关;中心透析中<2.1与死亡风险升高相关,≥2.3与死亡风险降低相关。

要点

  • 中心透析患者标准Kt/Vurea<2.1与死亡风险升高相关(aHR 1.11)。
  • 中心透析患者标准Kt/Vurea≥2.3与死亡风险降低相关(aHR 0.97)。
  • 居家透析患者标准Kt/Vurea与死亡、住院或转中心透析无关联。

核心结论

  • 当前标准Kt/Vurea目标对居家透析患者识别不良结局风险效用有限,但可能改善中心透析的风险分层。

研究设计与样本

  • 多变量回归分析透析标准Kt/Vurea与血压及代谢控制的关系,样本为居家透析2373例和中心透析109273例。
  • Cox生存模型分析标准Kt/Vurea与死亡、住院及居家透析转中心透析的关联。

主要发现

  • 标准Kt/Vurea<2.1者血压较高:居家透析高3.4 mm Hg(P<0.001),中心透析高0.9 mm Hg(P<0.001)。
  • 标准Kt/Vurea与代谢控制指标无临床意义关联,与透析模式无关。
  • 居家透析中标准Kt/Vurea与死亡、住院或转中心透析无关联。
  • 中心透析中标准Kt/Vurea<2.1与死亡风险升高相关(aHR 1.11;95%CI 1.07-1.14),≥2.3与死亡风险降低相关(aHR 0.97;95%CI 0.94-0.99),参照组为2.1至<2.3。
  • 限定于有残余肾功能数据的患者,透析及总标准Kt/Vurea与结局关系相似。

关键数值与推荐

  • 中心透析患者标准Kt/Vurea<2.1与死亡风险升高相关(aHR 1.11;95%CI 1.07-1.14)。
  • 中心透析患者标准Kt/Vurea≥2.3与死亡风险降低相关(aHR 0.97;95%CI 0.94-0.99)。
  • 居家透析患者标准Kt/Vurea<2.1者血压较2.1至<2.3者高3.4 mm Hg(P<0.001)。
  • 中心透析患者标准Kt/Vurea<2.1者血压较2.1至<2.3者高0.9 mm Hg(P<0.001)。

临床怎么用

  • 中心透析患者可考虑使用标准Kt/Vurea进行风险分层,<2.1提示死亡风险升高。
  • 居家透析患者不应仅依赖标准Kt/Vurea评估不良结局风险。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Patients undergoing hemodialysis with a frequency other than thrice weekly are not included in current clinical performance metrics for dialysis adequacy. The weekly standard Kt/Vurea incorporates treatment frequency, but there are limited data on its association with clinical outcomes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used multivariable regression to examine the association of dialysis standard Kt/Vurea with BP and metabolic control (serum potassium, calcium, bicarbonate, and phosphorus) in patients incidental to dialysis treated with home (n=2373) or in-center hemodialysis (n=109,273). We further used Cox survival models to examine the association of dialysis standard Kt/Vurea with mortality, hospitalization, and among patients on home hemodialysis, transfer to in-center hemodialysis. RESULTS: After adjustment for potential confounders, patients with dialysis standard Kt/Vurea <2.1 had higher BPs compared with patients with standard Kt/Vurea 2.1 to <2.3 (3.4 mm Hg higher [P<0.001] for home hemodialysis and 0.9 mm Hg higher [P<0.001] for in-center hemodialysis). There were no clinically meaningful associations between dialysis standard Kt/Vurea and markers of metabolic control, irrespective of dialysis modality. There was no association between dialysis standard Kt/Vurea and risk for mortality, hospitalization, or transfer to in-center hemodialysis among patients undergoing home hemodialysis. Among patients on in-center hemodialysis, dialysis standard Kt/Vurea <2.1 was associated with higher risk (adjusted hazard ratio, 1.11; 95% confidence interval, 1.07 to 1.14) and standard Kt/Vurea ≥2.3 was associated with lower risk (adjusted hazard ratio, 0.97; 95% confidence interval, 0.94 to 0.99) for death compared with standard Kt/Vurea 2.1 to <2.3. Additional analyses limited to patients with available data on residual kidney function showed similar relationships of dialysis and total (dialysis plus kidney) standard Kt/Vurea with outcomes. CONCLUSIONS: Current targets for standard Kt/Vurea have limited utility in identifying individuals at increased risk for adverse clinical outcomes for those undergoing home hemodialysis but may enhance risk stratification for in-center hemodialysis.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Rivara MB, Ravel V, Streja E, et al. Weekly Standard Kt/Vurea and Clinical Outcomes in Home and In-Center Hemodialysis. Clin J Am Soc Nephrol. 2018. PMID: 29326306. doi:10.2215/CJN.05680517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。